S Harnan

2.4k total citations
57 papers, 1.6k citations indexed

About

S Harnan is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, S Harnan has authored 57 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Surgery, 11 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in S Harnan's work include Breast Cancer Treatment Studies (8 papers), Asthma and respiratory diseases (7 papers) and Breast Lesions and Carcinomas (6 papers). S Harnan is often cited by papers focused on Breast Cancer Treatment Studies (8 papers), Asthma and respiratory diseases (7 papers) and Breast Lesions and Carcinomas (6 papers). S Harnan collaborates with scholars based in United Kingdom, Australia and United States. S Harnan's co-authors include Abdullah Pandor, Patrick Fitzgerald, A Pickering, Katy Cooper, Steve Goodacre, Yang Meng, Sue Ward, Paul Tappenden, Lynda Wyld and Ruth Wong and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and European Respiratory Journal.

In The Last Decade

S Harnan

54 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S Harnan United Kingdom 22 338 330 282 262 246 57 1.6k
Matthew J. Weiss Canada 22 210 0.6× 237 0.7× 385 1.4× 111 0.4× 237 1.0× 111 1.5k
Juhee Song United States 30 243 0.7× 563 1.7× 816 2.9× 236 0.9× 108 0.4× 160 2.8k
Johannes Hüsing Germany 26 146 0.4× 424 1.3× 480 1.7× 104 0.4× 231 0.9× 58 2.9k
Laura Giordano Italy 31 230 0.7× 873 2.6× 305 1.1× 152 0.6× 341 1.4× 165 3.3k
Philippe Gaudin France 32 120 0.4× 164 0.5× 438 1.6× 210 0.8× 94 0.4× 148 3.4k
Marcus W. Butler Ireland 18 99 0.3× 639 1.9× 361 1.3× 1.1k 4.1× 165 0.7× 51 2.4k
Deepak Bansal India 26 84 0.2× 317 1.0× 252 0.9× 65 0.2× 259 1.1× 248 2.5k
Katherine Van Loon United States 21 293 0.9× 267 0.8× 270 1.0× 115 0.4× 99 0.4× 126 1.7k
Maureen M. O’Brien United States 36 85 0.3× 306 0.9× 578 2.0× 174 0.7× 141 0.6× 151 3.7k
Michela Cinquini Italy 23 213 0.6× 354 1.1× 301 1.1× 85 0.3× 54 0.2× 71 2.0k

Countries citing papers authored by S Harnan

Since Specialization
Citations

This map shows the geographic impact of S Harnan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S Harnan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S Harnan more than expected).

Fields of papers citing papers by S Harnan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S Harnan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S Harnan. The network helps show where S Harnan may publish in the future.

Co-authorship network of co-authors of S Harnan

This figure shows the co-authorship network connecting the top 25 collaborators of S Harnan. A scholar is included among the top collaborators of S Harnan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S Harnan. S Harnan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cooper, Katy, Anthea Sutton, S Harnan, et al.. (2024). Systematic Review of Presymptomatic Treatment for Spinal Muscular Atrophy. International Journal of Neonatal Screening. 10(3). 56–56. 8 indexed citations
2.
Woods, Beth, Dina Janković, Benjamin Kearns, et al.. (2024). Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Health Technology Assessment. 28(28). 1–238. 3 indexed citations
3.
4.
Cooper, Katy, Anthea Sutton, S Harnan, et al.. (2024). Systematic Review of Newborn Screening Programmes for Spinal Muscular Atrophy. International Journal of Neonatal Screening. 10(3). 49–49. 9 indexed citations
5.
Rafia, Rachid, et al.. (2022). A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales. Value in Health. 25(5). 761–769. 14 indexed citations
6.
James, Marrissa Martyn‐St, et al.. (2018). Rapid diagnostic test for antenatal syphilis screening in low-income and middle-income countries: a systematic review and meta-analysis. BMJ Open. 8(2). e018132–e018132. 18 indexed citations
7.
Bermejo, Iñigo, Matt Stevenson, Katy Cooper, et al.. (2017). Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 36(2). 131–144. 19 indexed citations
8.
Uttley, Lesley, et al.. (2016). Building the Evidence Base of Blood-Based Biomarkers for Early Detection of Cancer: A Rapid Systematic Mapping Review. EBioMedicine. 10. 164–173. 35 indexed citations
9.
Pickering, A, Katy Cooper, S Harnan, et al.. (2015). Impact of prehospital transfer strategies in major trauma and head injury. The Journal of Trauma: Injury, Infection, and Critical Care. 78(1). 164–177. 34 indexed citations
10.
Harnan, S, Munira Essat, Tim Gomersall, et al.. (2015). Exhaled Nitric Oxide For The Diagnosis Of Asthma In Adults And Children: A Systematic Review. Value in Health. 18(7). A345–A345. 1 indexed citations
11.
Harnan, S, et al.. (2015). Pruning and prioritising: a case study of a pragmatic method for managing a rapid systematic review with limited resources. Evidence & Policy. 11(4). 589–601. 4 indexed citations
12.
Whyte, Sophie & S Harnan. (2014). Effectiveness and cost-effectiveness of an awareness campaign for colorectal cancer: a mathematical modeling study. Cancer Causes & Control. 25(6). 647–658. 9 indexed citations
13.
Tappenden, Paul, S Harnan, Lesley Uttley, et al.. (2013). The Cost Effectiveness of Dry Powder Antibiotics for the Treatment of Pseudomonas aeruginosa in Patients with Cystic Fibrosis. PharmacoEconomics. 32(2). 159–172. 18 indexed citations
14.
Uttley, Lesley, S Harnan, Anna Cantrell, et al.. (2013). Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis. European Respiratory Review. 22(130). 476–486. 20 indexed citations
15.
16.
Harnan, S, et al.. (2011). PHP58 Towards Cost-Effectiveness Analysis of the Health and Wellbeing Benefits of Urban Green Space: A Mapping Review. Value in Health. 14(7). A343–A343. 1 indexed citations
17.
Pickering, A, S Harnan, Patrick Fitzgerald, Abdullah Pandor, & Steve Goodacre. (2011). Clinical decision rules for children with minor head injury: a systematic review. Archives of Disease in Childhood. 96(5). 414–421. 78 indexed citations
18.
Harnan, S, Katy Cooper, Yang Meng, et al.. (2011). Magnetic resonance for assessment of axillary lymph node status in early breast cancer: A systematic review and meta-analysis. European Journal of Surgical Oncology. 37(11). 928–936. 62 indexed citations
19.
Cooper, Katy, S Harnan, Yang Meng, et al.. (2011). Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: A systematic review and meta-analysis. European Journal of Surgical Oncology. 37(3). 187–198. 91 indexed citations
20.
Meng, Yang, Sue Ward, Katy Cooper, S Harnan, & Lynda Wyld. (2010). Cost-effectiveness of MRI and PET imaging for the evaluation of axillary lymph node metastases in early stage breast cancer. European Journal of Surgical Oncology. 37(1). 40–46. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026